Search Result

Results for "

Tau protein aggregation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Tau Protein (24) Amylin Receptor (1) Amyloid-β (14) Apoptosis (1) Autophagy (2) Bacterial (1) Calcium Channel (1) Cholinesterase (ChE) (10) Dengue Virus (1) Dopamine Receptor (1) Ferroptosis (1) Flavivirus (1) Fungal (1) GSK-3 (4) HDAC (1) Histamine Receptor (2) HSP (1) Huntingtin (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Monoamine Oxidase (1) NOD-like Receptor (NLR) (1) OGA (1) Reactive Oxygen Species (ROS) (2) SOD (1) Tyrosine Hydroxylase (1) α-synuclein (3)
By Research Areas:	Cancer (1) Infection (1) Inflammation/Immunology (1) Neurological Disease (39)

By Targets:

Tau Protein (24)

Amylin Receptor (1)

Amyloid-β (14)

Apoptosis (1)

Autophagy (2)

Bacterial (1)

Calcium Channel (1)

Cholinesterase (ChE) (10)

Dengue Virus (1)

Dopamine Receptor (1)

Ferroptosis (1)

Flavivirus (1)

Fungal (1)

GSK-3 (4)

HDAC (1)

Histamine Receptor (2)

HSP (1)

Huntingtin (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

Monoamine Oxidase (1)

NOD-like Receptor (NLR) (1)

OGA (1)

Reactive Oxygen Species (ROS) (2)

SOD (1)

Tyrosine Hydroxylase (1)

α-synuclein (3)

By Research Areas:

Cancer (1)

Infection (1)

Inflammation/Immunology (1)

Neurological Disease (39)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Tau Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99471

Bepranemab UCB 0107	Tau Protein	Neurological Disease
Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of **tau protein*. Bepranemab inhibits the seeding, aggregation* of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease .

HY-19948

Leucomethylene blue mesylate 5+ Cited Publications TRx0237 mesylate; Methylene blue leuco base mesylate	Tau Protein	Neurological Disease
Leucomethylene blue (TRx0237) mesylate, an orally active second-generation *tau* protein aggregation inhibitor (K_i of 0.12 μM), could be used for the study of Alzheimer's Disease. Leucomethylene blue mesylate is a common reduced form of Methylene Blue, Methylene Blue is a member of the thiazine class of dyes .

HY-P4808

PHF6	Amyloid-β Autophagy	Neurological Disease
PHF6 (VQIVYK) is a self-assembly sequence capable of initiating the full-length tau protein aggregation and is mapped to the third microtubule-binding repeat region of the tau protein .

HY-P99648

Gosuranemab BMS-986168; IPN007; BIIB092	Tau Protein	Neurological Disease
Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .

HY-P9995

Posdinemab JNJ-63733657	Tau Protein	Neurological Disease
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .

HY-156586

Egalognastat ASN90	OGA Tau Protein	Neurological Disease
Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC₅₀ value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease) .

HY-19738

NQTrp	Tau Protein	Neurological Disease
NQTrp, an aromatic naphthoquinone-tryptophan hybrid molecule, an inhibitor of the aggregation of the **tau protein** with generic anti-amyloidogenic effects. NQTrp inhibits the in vitro aggregation of hexapeptide ( ⁴¹GCWMLY ⁴⁶ within the N-terminus of γD-crystallin) as well as full-length γD-crystallin .

HY-153430

Aβ/tau aggregation-IN-3	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC₅₀ of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity .

HY-153427

Tau protein aggregation-IN-1	Tau Protein	Neurological Disease
Tau protein aggregation-IN-1 (Compound 0c) is a **Tau protein** aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies .

HY-P4808A

PHF6 TFA	Amyloid-β Autophagy	Neurological Disease
PHF6 (VQIVYK) TFA is a self-assembly sequence capable of initiating the full-length tau protein aggregation. PHF6 TFA is mapped to the third microtubule-binding repeat region of the tau protein .

HY-P4933

Tau Peptide (255-314) (Repeat 2 Domain) (human) Tau-F protein (255-314)	Tau Protein	Neurological Disease
Tau Peptide (255-314) (Repeat 2 Domain) (human) (Tau-F protein (255-314)) is a polypeptide. Tau Peptide (255-314) (human) is the 255-314 fragment of Tau-F (also known as Tau-4, the 2N4 isoform), a major isoform of the Tau protein. Tau Peptide (255-314) (human) contains two core driving sequences for Tau aggregation, namely PHF6* (275-280, VQIINK) and PHF6 (306-311, VQIVYK), and spans the C-terminal half of repeat domain R1, the entire repeat domain R2, and the N-terminal half of repeat domain R3 within the microtubule-binding region (MTBR).

HY-138643

Cl-NQTrp	Amyloid-β	Neurological Disease
Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein .

HY-N3187

Nimbin	Flavivirus Dengue Virus Fungal Bacterial Histamine Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Nimbin is an orally active intermediate limonoid found in Azadirachta. Nimbin prevents *tau* aggregation and increases cell viability. Nimbin is effective inhibits the *envelope protein* of dengue virus**. Nimbin has anti-inflammatory, antipyretic, antifungal, antihistamine, antiseptic, antioxidant, anti-cancer and anti-viral properties. Nimbin is promising for research of neurodegenerative diseases and viral infections .

HY-159083

DN5355	Amyloid-β	Neurological Disease
DN5355 is a small molecule compound that targets amyloid β protein (Aβ) and hyperphosphorylated *tau* protein. DN5355 can inhibit the aggregation of Aβ and *tau* protein and disaggregate the formed Aβ and *tau* protein fibers. DN5355 can be used in the study of Alzheimer's disease .

HY-W835959

ACI-3024	Tau Protein	Neurological Disease
ACI-3024 is an an orally active and highly selective **Tau protein aggregation** inhibitor. ACI-3024 decrease the β-sheet content and seeding properties of pathological Tau from different Tauopathies, leading to a significant rescue of the Tau-induced neurodegeneration and neuroinflammation in a cellular model. ACI-3024 is promising for research of neurodegenerative diseases .

HY-P2516

Tau Peptide (275-305) (Repeat 2 domain)	Tau Protein	Neurological Disease
Tau Peptide (275-305) (Repeat 2 domain) is the Alzheimer's Tau fragment R2, corresponding to the second repeat unit of the microtubule-binding domain, which is believed to be pivotal to the biochemical properties of full tau protein. Tau Peptide (275-305) specifically coordinates with group IIB metal ions (Zn²⁺, Cd²⁺, Hg²⁺), which can induce their conformational changes and significantly promote their pathological accumulation. Tau Peptide (275-305) can be used to study the role of heavy metals in neurodegenerative diseases .

HY-146135

Tau-aggregation-IN-1	Microtubule/Tubulin Dopamine Receptor	Neurological Disease
Tau-aggregation-IN-1 (Compound D-519) is a *tau441* protein aggregation inhibitor with an IC₅₀ of 21 µM. Tau-aggregation-IN-1 is also a dopamine D₂ and D₃ receptor agonist .

HY-109116A

Hydromethylthionine dihydrobromide Leukomethylene blue dihydrobromide; LMTM dihydrobromide	Tau Protein	Neurological Disease
Hydromethylthionine dihydrobromide (Leukomethylene blue dihydrobromide) is a potent inhibitor of *TAU* protein aggregation. Hydromethylthionine dihydrobromide reduces neurodegeneration by interacting with *TAU* proteins and preventing them from forming neurotoxic aggregates. Hydromethylthionine dihydrobromide can be used in the study of Alzheimer's disease and other *TAU* related disorders .

HY-141541

MPT0G413	HDAC Tau Protein	Neurological Disease
MPT0G413 (Compound 6) is a potent, selective, orally active and brain-penetrant HDAC6 inhibitor with an IC₅₀ of 3.92 nM. MPT0G413 decreases not only the level of phosphorylation of **tau proteins** but also the aggregation of tau proteins. MPT0G413 can ameliorate the impaired learning and memory. MPT0G413 can be used for the research of neurological disease, such as Alzheimer's disease .

HY-179377

Aha1/Hsp90-IN-2	HSP Tau Protein	Neurological Disease
Aha1/Hsp90-IN-2 is a selective inhibitor of the Hsp90/Aha1 interaction, with its IC₅₀ being 1.46 μM. Aha1/Hsp90-IN-2 inhibits the activation of Hsp90 ATPase activity mediated by Aha1 by specifically blocking the binding of Hsp90 to Aha1, thereby reducing *tau* protein aggregation. Aha1/Hsp90-IN-2 can be used for the study of neurodegenerative diseases, such as Alzheimer's disease .

HY-174272

GSK-3β inhibitor 27	GSK-3 Amyloid-β	Neurological Disease
GSK-3β inhibitor 27 (Compound 1c) is a reversible and competitive GSK-3β inhibitor with an IC₅₀ value of 2.2 μM. GSK-3β inhibitor 27 inhibits tau hyperphosphorylation, reduces Aβ protein aggregation and possesses metal chelation and neuroprotective potential. GSK-3β inhibitor 27 is promising for research of neurodegenerative diseases (such as Alzheimer’s disease) .

HY-155365

hAChE-IN-5	Cholinesterase (ChE) GSK-3 Amyloid-β	Neurological Disease
hAChE-IN-5 (compound 49) is a potent hAChE and hBuChE inhibitor with IC₅₀ values of 0.17 μM and 0.17 μM, respectively. hAChE-IN-5 shows potent GSK3β inhibition with an IC₅₀ value of 0.21 μM. hAChE-IN-5 is used as *tau* protein aggregation and Aβ1-42 self-aggregation inhibitor. hAChE-IN-5 can bind virtually with the PAS affecting Aβ aggregation, thus preventing Aβ-dependent neurotoxicity. hAChE-IN-5 can penetrate BBB and has the potential for multi-targeted anti-Alzheimer's agents research .

HY-161448

Tau-aggregation-IN-3	Tau Protein	Neurological Disease
Tau-aggregation-IN-3 (compound 9) a *Tau* protein aggregation inhibitor (TAI). Tau-aggregation-IN-3 shows activity in cell-based aggregation inhibition experiments (EC₅₀=4.816 μM). Tau-aggregation-IN-3 can be used in Alzheimer's disease research .

HY-159945

tau Protein/α-synuclein-IN-2	α-synuclein	Neurological Disease
Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating *tau* and α-syn inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces α-syn oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of *tau* aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.

HY-149273

hBChE-IN-1	Cholinesterase (ChE) Amyloid-β Tau Protein	Neurological Disease
hBChE-IN-1 (compound 4), a quinolizidinyl derivative, is a potent hBChE inhibitor (IC₅₀=7 nM) and highly selective over hAChE. hBChE-IN-1 shows inhibitory activity against *tau* and Aβ₄₀ protein aggregation, with IC₅₀ values of 20 and 4.3 μM, respectively. hBChE-IN-1 can be used for Alzheimer's disease research .

HY-150585

BuChE-IN-5	Amyloid-β Cholinesterase (ChE) Tau Protein	Neurological Disease
BuChE-IN-5 (compound 25b) is a potent BuChE inhibitor with an IC₅₀ value of 1.94 μM. BuChE-IN-5 efficiently inhibits aggregation Aβ and **tau protein** in Escherichia coli. BuChE-IN-5 also has free radical scavenging capacity and antioxidant activity. BuChE-IN-5 can be used for researching Alzheimer’s disease .

HY-175658

AChE/BChE-IN-29	Cholinesterase (ChE) Amyloid-β Tau Protein	Neurological Disease
AChE/BChE-IN-29 is an AChE/BChE inhibitor. AChE/BChE-IN-29 exhibits balanced dual cholinesterase inhibitory activity with IC₅₀ values of 2.1 μM for Electrophorus electricus AChE (eeAChE) and 6.3 μM for equine serum butyrylcholinesterase (eqBChE). AChE/BChE-IN-29 effectively inhibits amyloid-β (Aβ₄₂) aggregation and *tau* protein aggregation in E. coli cell models. AChE/BChE-IN-29 can be used for the study of Alzheimer’s disease (AD) .

HY-155366

hAChE-IN-6	Cholinesterase (ChE) GSK-3	Neurological Disease
hAChE-IN-6 (compound 51) is a brain penetrant AChE inhibitor with an IC₅₀ of 0.16 μM. hAChE-IN-6 also inhibits hBuChE and GSK3β with IC₅₀ values of 0.69 μM and 0.26 μM, respectively. hAChE-IN-6 inhibits tau protein and Aβ1-42 self-aggregation, and can be used for Alzheimer's disease (AD) research .

HY-170417

hAChE/hBuChE/GSK-3β-IN-1	Cholinesterase (ChE) GSK-3	Neurological Disease
hAChE/hBuChE/GSK-3β-IN-1 (Compound 6c) is a BBB-penetrable and multi-target anti-Alzheimer's disease compound. hAChE/hBuChE/GSK-3β-IN-1 is the inhibitors of hAChE (IC₅₀: 28.88 nM), hBuChE (IC₅₀: 131.90 nM) and GSK-3β (IC₅₀: 51.42 nM). hAChE/hBuChE/GSK-3β-IN-1 is the *tau* and Aβ protein aggregation inhibitors .

HY-159898

AChE/BChE-IN-23	Cholinesterase (ChE) Amyloid-β Tau Protein NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) Mitochondrial Metabolism	Neurological Disease
AChE/BChE-IN-23 (Compound 6e) is an AChE/BChE inhibitor (IC₅₀: 0.91 μM, 1.19 μM and 1.01 μM for hAChE, eq BChE and hBChE, respectively). AChE/BChE-IN-23 has antioxidant activity and inhibits Aβ1-42 and *Tau* protein aggregation. AChE/BChE-IN-23 also inhibits microglial activation by reducing ROS release and mitochondrial injury. AChE/BChE-IN-23 suppresses NLRP3 inflammasome and pro-inflammatory cytokines in human microglial cells. AChE/BChE-IN-23 also reverses the Scopolamine (HY-N0296)-induced memory impairment in mice model .

HY-162812

H3R antagonist 4	Apoptosis Cholinesterase (ChE) Tau Protein Ferroptosis Histamine Receptor	Neurological Disease
H3R antagonist 4 (compound 11L) was a dual inhibitor of cholinesterase and histamine receptor (H3R), with corresponding IC₅₀ of 7.04 μM (eeAChE), 9.73 μM (hAChE)(reversible) and 1.09 nM (H3R) , respectively. H3R antagonist 4 inhibited the aggregation of Aβ_1-42 induced by itself and Cu ²⁺ (95.48% and 88.63%) , and degraded the Aβ_1-42 fibrils induced by itself and Cu ²⁺ (80.16% and 89.30%) . H3R antagonist 4 chelate biometals such as Cu ²⁺, Zn ²⁺, Al ³⁺, and Fe ²⁺. H3R antagonist 4 significantly reduced *tau* protein hyperphosphorylation induced by Aβ_1-42 and inhibited RSL-3-induced apoptosis and ferroptosis in PC12 cells. H3R antagonist 4 had the best blood-brain barrier permeability and intestinal absorption in hCMEC/D3 and hPepT1-MDCK cells.H3R antagonist 4 ameliorates learning and memory impairment in a mouse model of Alzheimer's disease induced by scopolamine (HY-N0296) .

HY-185357

TAU-IN-6	Tau Protein	Neurological Disease
TAU-IN-6 (Compound 13) is a *Tau* protein misfolding and aggregation inhibitor. TAU-IN-6 inhibits stress granules composed of tau and TIA1. TAU-IN-6 is applicable for Alzheimer's disease research .

HY-P99648A

Gosuranemab (powder) BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)	Tau Protein	Neurological Disease
Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .

HY-183375

AChE/BuChE/BACE-1-IN-1		Neurological Disease
AChE/BuChE/BACE-1-IN-1 is a blood-brain barrier-permeable multi-target inhibitor of AChE/BuChE/BACE, with IC₅₀ values of 0.387 μM, 0.430 μM, and 0.531 μM against AChE, BuChE, and BACE-1, respectively. AChE/BuChE/BACE-1-IN-1 reduces the aggregation of β-amyloid protein (Aβ) and hyperphosphorylated tau protein (p-tau). AChE/BuChE/BACE-1-IN-1 can be used for the research of Alzheimer's disease .

HY-119492

Phenchlobenpyrrone	Calcium Channel Cholinesterase (ChE) Amyloid-β Tau Protein	Neurological Disease
Phenchlobenpyrrone is a highly selective neuronal calcium antagonist that crosses the blood-brain barrier. Phenchlobenpyrrone mildly inhibits AChE activity. Phenchlobenpyrrone inhibits Aβ aggregation and promotes the clearance of Aβ oligomers. Phenchlobenpyrrone reduces abnormal phosphorylation of *Tau* protein. Phenchlobenpyrrone may be used in research on Alzheimer's disease .

HY-182304

CLR01 sodium	Amyloid-β α-synuclein Amylin Receptor Tau Protein SOD	Neurological Disease
CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, *tau* protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) .

HY-182893

SK-129	α-synuclein Reactive Oxygen Species (ROS) Tyrosine Hydroxylase	Neurological Disease
SK-129 is a blood-brain barrier-permeable inhibitor of α-synuclein (αS) oligomers with a K_d of 221 nM. SK-129 preferentially binds to neurotoxic αS oligomers over physiological αS monomers, inhibits αS aggregation, blocks the interaction and co-aggregation of αS with tau protein, and prevents the maturation of αS-tau condensates into amyloid aggregates. SK-129 reduces ROS production, rescues dopaminergic neuron degeneration, improves motor function, restores endogenous dopamine synthesis, increases the number of Tyrosine Hydroxylase-positive neurons, prevents brain histopathological changes, alleviates neuroinflammation, and improves survival rates in relevant models. SK-129 can be used in research related to Parkinson's disease (PD) and Lewy body dementia (LBD) .

HY-180346

Hepta-histidine	Huntingtin	Neurological Disease
Hepta-histidine is an inhibitor of Ku70-Huntingtin protein interaction. Hepta-histidine can reverse the morphological abnormalities of primary neurons differentiatied from hiPSCs. Hepta-histidine prolongs the lifespan in severe Huntington’s disease R6/2 mouse model. Hepta-histidine ameliorates DNA damage in vitro. Hepta-histidine can be used to study anti-aggregation agent against Tau-associated neurodegenerative diseases such as Alzheimer’s disease and Huntington’s disease .

HY-180842

MAO-B-IN-50	Monoamine Oxidase Amyloid-β Tau Protein Cholinesterase (ChE)	Neurological Disease
MAO-B-IN-50 (Compound C20) is a selective MAO-B inhibitor with an IC₅₀ value of 0.06 μM. MAO-B-IN-50 shows good inhibitory effects on the aggregation of Aβ40/42 and *Tau* proteins, with overall IC₅₀ values around 1 μM. MAO-B-IN-50 exhibits potent and selective AChE inhibition (IC₅₀ = 1.78 μM). MAO-B-IN-50 can be used in the research of Alzheimer's disease .

Cat. No.	Product Name	Type